Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The SARS-CoV-2 vaccine roll-out has been successful around the world. However, there are increasing concerns about adverse events. We report two pediatric cases of Multisystem-Inflammatory-Syndrome (MIS-C) with neurological involvement that occurred after SARS-CoV-2 vaccination and unknown recent SARS-CoV-2 infection. Brain magnetic resonance revealed mild-encephalopathy with reversible-splenial-lesion in both cases and complete resolution within 4 weeks. In conclusion, this report aims to describe rare emerging clinical entities that can help pediatricians to make an early diagnosis and to provide appropriate treatment. Multisystem-Inflammatory-Syndromes following COVID-19 vaccination remain rare events. When a history of a recent contact with SARS-CoV-2 is present, a careful evaluation by the clinicians in charge of immunization activities is suggested prior to proceeding with the vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319257 | PMC |
| http://dx.doi.org/10.3390/vaccines10071136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex distribution in tuberculosis disease in children, adolescents, and adults in a low-incidence country: a retrospective population-based cohort study.
Swiss Med Wkly
May 2025
Mycobacterial and Migrant Health Research Group, University of Basel Children's Hospital Basel and Department of Clinical Research, University of Basel, Basel, Switzerland.
Aim: Globally, tuberculosis incidence shows notable sex disparity, with higher rates observed in males. While this pattern is well documented in adults from high-incidence countries, the influence of sex on tuberculosis incidence in children and adolescents, particularly in low-incidence settings, remains unclear. This study investigated sex-specific tuberculosis incidence rates across all age groups, focusing on adolescents, in a low-incidence country.
View Article and Find Full Text PDFObjectives: The primary aim of this study was to compare resource utilization between lower and higher-risk brief resolved unexplained events (BRUE) in the general (GED) and pediatric (PED) emergency departments.
Methods: We conducted a retrospective chart review of BRUE cases from a large health system over 6-and-a-half years. Our primary outcome was the count of diagnostic tests per encounter.
Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFInterdisciplinary management of paediatric chronic and complex pain: the experience of a specialised outpatient clinic in Italy.
Eur J Pediatr
September 2025
Paediatric Pain and Palliative Care Service, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
Purpose: This study aimed to describe the structure, patient characteristics, and preliminary clinical outcomes of a dedicated interdisciplinary outpatient clinic for paediatric chronic and complex pain in Italy, with a focus on the feasibility of implementing a biopsychosocial care model.
Methods: We conducted a retrospective review of all patients referred to the Paediatric Specialised Pain Clinic of the University of Padua between January 2023 and May 2024. Data on demographics, clinical diagnoses, pain characteristics, treatments, and follow-up outcomes were collected.
Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults: a living systematic review and meta-analysis.
Thorax
September 2025
Usher Institute, The University of Edinburgh, Edinburgh, UK
Background: The long-acting monoclonal antibody nirsevimab and respiratory syncytial virus (RSV) vaccines became available for prevention of severe RSV-associated disease in 2023. While clinical trials showed good efficacy and safety, their restrictive inclusion criteria, small sample sizes and short follow-up limit generalisability. We aimed to summarise real-world evidence on the effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults.
View Article and Find Full Text PDF